Fazer is preparing to launch foods containing Solein protein in Europe after a positive safety opinion from the European Food Safety Authority. Final EU authorisation is still required before the ingredient can be sold there.

The Finnish food group announced its plans on 9 November. It has not named European launch products, retailers or an on-sale date.

Solein is a microbial protein developed by Solar Foods. It is produced through gas fermentation using a naturally occurring microbe. It is an ingredient for food manufacturers, rather than a finished consumer product.

For supermarket buyers, the immediate distinction is between a safety assessment and permission to sell. EFSA’s opinion covers the proposed conditions of use. It does not itself authorise European shelf launches.

Solar Foods now expects the remaining EU process to take seven to nine months. That replaces its earlier expectation of approval during 2026. The estimate points to 2027, but remains a company forecast.

The European Commission must next prepare an implementing act for a vote by representatives of EU member states. Any eventual launch must follow the categories and conditions in the final authorisation.

Fazer is among the Finnish FMCG producers developing products around alternative ingredients. Its relationship with Solar Foods began in 2019. Fazer is also an investor and describes itself as Solar Foods’ largest shareholder.

“We have the readiness to launch Solein® products for consumers as soon as the final regulatory approval is granted in Europe,” said Heli Anttila, Fazer’s vice-president for research and product development.

The work has already reached consumers outside Europe. Fazer introduced a Solein snack bar in Singapore in 2024. It tested snack products and oat drinks at a San Francisco industry event in 2025.

Those pilots examined taste, texture and consumer response. They do not establish which formats will reach European supermarkets.

The ingredient’s manufacturing process offers a different supply model from crop and livestock proteins. Solar Foods says production does not depend on agricultural land or local weather. That is a potential sourcing advantage, rather than evidence of lower prices or unlimited supply.

The next commercial test is scale. Solar Foods links progress on customer agreements and financing to its planned Factory 02 investment decision. Buyers will need to distinguish available production from capacity still awaiting investment.

For procurement teams, the questions extend beyond protein content. They include approved applications, recipe performance, ingredient specifications and dependable delivery volumes. Product development can advance while purchasing commitments remain conditional.

Food safety systems and novel-food authorisation serve different purposes. A supplier’s certification does not replace permission to market a new ingredient. Retailers will need the final authorisation terms when assessing finished products.

Fazer’s next step is to turn its development work into a confirmed European range once approval allows it. Until then, the product list and launch timetable remain open.

Editor’s Note: Based on Fazer’s and Solar Foods’ announcements dated 9 November 2026. GTN distinguishes the positive EFSA opinion from final EU authorisation and the manufacturer’s estimated timetable.